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ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GIA Case of Unexplained Cutaneous Lesions, Cholestatic Hepatitis,
and Noncirrhotic Portal Hypertension in a Female Patient
Joana Carvão, Vítor Magno Pereira, and Luís Jasmins
Gastroenterology Department, Hospital Central do Funchal, Funchal, PortugalQuestion: A 57-year old woman with a previous history of contrast-related anaphylaxis was referred to the gastroenter-
ology department with worsening liver function tests. She developed recurrent abdominal pain, diarrhea, significant weight
loss, pruriginous generalized skin rash, and increased abdominal volume over 1 year.
Physical examination revealed generalized small reddish monomorphic macules on the trunk and thighs (Figure A),
hepatosplenomegaly, peripheral lymphadenopathy, and ascites. Blood tests showed normocytic normochromic anemia
(hemoglobin 9.4 g/dL), monocytosis (1.3  103/mL), thrombocytopenia (97 103/mL), slight international normalized ratio
prolongation, and a marked elevation of cholestasis parameters without jaundice (aspartate aminotransferase, 60 U/L;
alanine aminotransferase, 56 U/L; gamma-glutamyl transferase, 324 U/L; and alkaline phosphatase, 1277 U/L).
Abdominal Doppler ultrasound examination and a computed tomography scan revealed homogeneous hep-
atosplenomegaly (without signs of chronic liver disease), signs of portal hypertension without thrombosis of the spleno-
portal axis, moderate ascites, and intra-abdominal, axillary, and inguinal lymphadenopathies. Upper endoscopy showed
esophageal varices and portal hypertensive gastropathy.
Laboratory studies for chronic hepatopathy, infectious agents, and angiotensin-converting enzyme were negative. Bone
marrow biopsy revealed granulomatous myelitis, and both lymphadenopathy and skin biopsies showed increased mono-
nuclear cells.Gastroenterology 2020;159:e13–e15
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Because the previous workup did not provide a diagnosis, a percutaneous liver biopsy was performed, and revealed
moderate expansion of portal structures, with irregular contour (Figure B) and infiltration with numerous mastocytes,
occasionally in an atypical form (arrow in Giemsa stain in Figure C), and focal necrosis with no evidence of fibrosis. These
findings were confirmed in immunostaining, revealing C-KIT positivity. Serum trypsin levels were >20 ng/L. A second look
revision of skin and bone marrow biopsies was obtained, revealing occasional scattered mastocytes (C-KITþ).
What is the most likely diagnosis in this patient?
See the Gastroenterology web site (www.gastrojournal.org) for more information on submitting your favorite
image to Clinical Challenges and Images in GI.
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ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GIAnswer to: Image 6: Aggressive Systemic Mastocytosis
Together these findings were consistent with the diagnosis of aggressive systemic mastocytosis (SM). SM is characterized by
organ infiltration of abnormal mast cells with or without cutaneous involvement.1 Further genetic testing revealed D816V
mutation in the c-Kit gene.
Clinical manifestations are related to the infiltration of monoclonal mast cells in several organs (eg, hepatosplenomegaly,
lymphadenopathies) and to the release of mast cell mediators (eg, urticaria, diarrhea, abdominal cramping).1 Cutaneous
involvement in adult-onset SM typically consists of small monomorphic maculopapular lesions, predominantly on the trunk
and thighs, such as our patient.2 Gastrointestinal and liver involvement are seen in 80% of the patients with SM and have
a broad spectrum of manifestations.3 Liver function tests are frequently abnormal with a typical elevation of alkaline
phosphatase. The latter correlates with liver size, amount of liver fibrosis and mast cell infiltrate.3 Characteristic biopsy
findings include, inflammatory cellular infiltrates (100%), anisocytosis (100%), increased fibrosis (14%–100%), hepatocyte
changes, including focal necrosis (59%), extramedullary hematopoiesis (54%), cirrhosis (15%), portal venopathy or veno-
occlusive disease (12%), and cholestasis (8%). Inflammatory infiltrates reveal an increased number of mast cells, mostly
distributed in the portal area.3 Noncirrhotic portal hypertension and ascites occur owing to the blocking of sinusoidal and
venous flow by massive mastocyte infiltration and implicate a poorer prognosis.
The diagnosis of SM may be delayed for several months or years owing to a complex clinical scenario. This case was
particularly challenging because biopsies did not initially provide the diagnosis. In fact, the first suspicion was of lym-
phoproliferative disease or sarcoidosis. Therefore, a high level of clinical suspicion up front for SM and a multidisciplinary
team approach are essential for the diagnosis.
Cytoreductive therapy is frequently required in aggressive SM to ameliorate disease-related organ dysfunction. Phar-
macologic agents directed at MC degranulation (eg, H1/H2-antagonists) should also be considered for symptom alleviation.1
The patient was started on cladribine, and laboratory workup at 6-month revealed significant improvement, with
normalization of blood count, coagulation parameters, and liver function tests (Table 1).Table 1. Blood Tests from Admission and 6 Months after Therapy
Admission 6 Months after Therapy
Leucocytes (103/mL) 11 3.3
Monocytes (103/mL) 1,3 0.8
Hemoglobin (g/dL) 9,4 11,3
Platelets (103/mL) 97 176
International normalized ratio 1,35 -
Prothrombin time (sec) 15,2 -
Aspartate aminotransferase/alanine aminotransferase (U/L) 60/56 24/12
Gamma-glutamyl transferase/alkaline phosphatase (U/L) 324/1277 156/503
Albumin (g/L) 33,6 35,9Clinicians should consider infiltrative disease, particularly SM, as a differential diagnosis in cases of portal hypertension
of unknown etiology, especially in a patient with a history of anaphylaxis and monomorphic maculopapular skin lesions.
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